Change 5-day change 1-year change 3-year change Capi.($)
-16.67%-16.67% - - 4.97K
-0.53%-1.99%+29.27%-6.89% 195B
-10.99%-10.07%-4.82%-30.04% 126B
-0.88%-7.76%-32.17%+3.98% 124B
-1.33%+1.31%-58.38%-18.75% 64.2B
-0.53%-6.15%+10.44%-8.66% 48.68B
+1.25%+0.60%-23.47%-31.77% 43.83B
+2.00%-1.73%+18.58%+4.11% 37.52B
+2.80%-2.35%+30.49%+27.30% 36.09B
-1.41%+1.45%-25.00%-10.98% 28.24B
Average -1.69%-3.15%-6.12%-7.97% 78.1B
Weighted average by Cap. -0.69%-3.86%-2.96%-9.70%
Logo SpectraScience, Inc.
SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.
Employees
-